Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04094090 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia
A Phase 2 study of Keratoconus and Pellucid Marginal Corneal Degeneration, sponsored by Goodman Eye Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT04094090: Recruiting Phase 2 study of Keratoconus and Pellucid Marginal Corneal Degeneration, sponsored by Goodman Eye Center.
NCT04094090 is a Phase 2 study of Keratoconus and Pellucid Marginal Corneal Degeneration that is actively recruiting participants, run by Goodman Eye Center. The registered enrollment target is 500 participants, below the 1,157-participant average among 21 other Keratoconus trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04094090, a Phase 2 study of Keratoconus and Pellucid Marginal Corneal Degeneration, is actively recruiting participants, sponsored by Goodman Eye Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing corneal cross-linking (CXL) for the treatment of ectatic disorders.
Primary Outcome
Change in BSCVA compared to baseline.
Conditions Studied
Interventions
- COMBINATION_PRODUCT PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Study Locations (1)
California
- Goodman Eye Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-10-19 |
| Est. Completion | 2029-10-19 |
| Phase | Phase 2 |
What NCT04094090 shows while recruiting
NCT04094090 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,157-participant average among 21 other Keratoconus trials with a reported enrollment target (57% lower).
The record links to 3 conditions, with Keratoconus appearing as the primary indexed condition, and to 1 intervention - of which PXL-330 Platinum device for crosslinking with Peschke riboflavin solution is the first listed.
NCT04094090 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04094090 about?
NCT04094090 is a clinical study titled "Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia". To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing corneal cross-linking (CXL) for the treatment of ectatic disorders.
What is the current status of trial NCT04094090?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2019-10-19. Estimated completion is 2029-10-19.
What conditions does trial NCT04094090 study?
This clinical trial studies the following conditions: Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Ectasia.
What interventions are being tested in trial NCT04094090?
The interventions under investigation include: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04094090?
This trial is sponsored by Goodman Eye Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04094090 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04094090's enrollment target sits among peer trials
500 3rd of 21 higher than 19 of 21 other Keratoconus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Keratoconus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning
RECRUITING · Phase 2
-
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
RECRUITING · Phase 2
-
Comparison of Standard vs. Accelerated Corneal Crosslinking
RECRUITING · Phase 2
-
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
RECRUITING
-
OCT in Diagnosis of Irregular Corneas
RECRUITING
-
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI